Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.

Guardado en:
Detalles Bibliográficos
Autores principales: Georgia Zoumpoulidou, Carlos Alvarez-Mendoza, Caterina Mancusi, Ritika-Mahmuda Ahmed, Milly Denman, Christopher D. Steele, Maxime Tarabichi, Errin Roy, Lauren R. Davies, Jiten Manji, Camilla Cristalli, Katia Scotlandi, Nischalan Pillay, Sandra J. Strauss, Sibylle Mittnacht
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/29d2b65339524853a5548dbf68b35ca4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/29d2b65339524853a5548dbf68b35ca4

Ejemplares similares